Tobramycin
Tobrex is an antibiotic that acts on many species of microorganisms that can infect the eye.
Tobrex is intended for use in the treatment of external eye infections and their surroundings in adults and children over 1 year of age, caused by bacteria sensitive to its active substance - tobramycin.
Before starting to use Tobrex, discuss it with your doctor or pharmacist:
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
If you are using other eye drops or ointments, keep a gap of at least 5 minutes between administrations. Eye ointments should be used last.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, consult your doctor before using this medicine.
Pregnancy
Tobrex may be used during pregnancy only if it is absolutely necessary.
Breastfeeding
Using Tobrex is not recommended during breastfeeding. The doctor will decide whether to continue or stop breastfeeding or continue or stop treatment, taking into account the benefits of breastfeeding for the baby and the benefits of treatment for the mother.
Tobrex has no influence or negligible influence on the ability to drive and use machines.
For some time after administering Tobrex, vision may be blurred.
Do not drive or operate machines until this symptom subsides.
During treatment of eye inflammation, wearing contact lenses is not recommended.
Always use this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist.
In mild or moderate diseases, apply a small amount (about 1.5 cm) of ointment to the conjunctival sac of the infected eye(s) two or three times a day.
In severe cases, apply a small amount (about 1.5 cm) of ointment to the conjunctival sac of the infected eye(s) every three to four hours for the first two days, then two to three times a day, until the infection subsides.
Tobrex eye ointment can be used before bedtime, in combination with Tobrex eye drops, solution, during the day.
Usually, the medicine is used for 7 to 10 days. The medicine should be used for as long as the doctor recommends.
Tobrex eye ointment can be used in children over 1 year of age in the same doses as in adults. The safety and efficacy of using the medicine in children under 1 year of age have not been established, and no data are available for such use.
In elderly patients, use the same dose as in adults.
The safety and efficacy of using Tobrex in patients with liver and kidney disorders have not been established.
Method of administration
Tobrex is exclusivelyintended for use in the eye.
1
2
Method of administration
In case of overdose, excess medicine can be rinsed from the eye with warm water.
No side effects are expected. Do not administer additional ointment. Administer the next dose at the usual time.
If you miss a dose of Tobrex, continue treatment by administering the next dose according to the dosing schedule. If it is almost time for the next dose, skip the missed dose and continue treatment according to the recommended dosing schedule. Do not use a double doseto make up for a missed dose.
If you are using other eye drops or ointments, keep a gap of at least 5 minutes between administrations. Eye ointments should be used last.
Like all medicines, Tobrex can cause side effects, although not everybody gets them.
If you experience allergic reactions, including rash, face, lip, tongue, and/or throat swelling, which may cause difficulty breathing or swallowing, or other serious side effects, stop using Tobrex and contact your doctor or the Emergency Department of your nearest hospital immediately.
The following side effects have been reported during the use of Tobrex:
Common side effects (may affect up to 1 in 10 people)
Eye symptoms: eye discomfort, eye redness.
Uncommon side effects (may affect up to 1 in 100 people)
Eye symptoms: inflammation of the eye surface, corneal damage, vision disturbances, blurred vision, eyelid redness, eye and eyelid swelling, eye pain, dry eye, eye discharge, eye itching, increased tear production.
General symptoms: allergy (hypersensitivity), headache, hives, skin inflammation, reduced eyelash growth or eyelash loss, skin depigmentation, itching, and dry skin.
Frequency not known (frequency cannot be estimated from available data)
Eye symptoms: eye allergy, eye irritation, eyelid itching.
General symptoms: severe allergic reactions, severe skin reactions (Stevens-Johnson syndrome, erythema multiforme), rash.
If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
To prevent infection of the ointment, discard the tube 4 weeks after first opening.
Write the date of opening in the space below.
Date of first opening: …………….
Keep the medicine out of the sight and reach of children.
Store below 25°C. Do not store in the refrigerator or freeze.
Keep the tube tightly closed.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
1 tube containing 3.5 g of ointment, in a cardboard box.
For more detailed information, consult the marketing authorization holder or parallel importer.
Novartis Hrvatska d.o.o.
Radnička cesta 37b
10 000 Zagreb, Croatia
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona, Spain
S.A. Alcon-Couvreur N.V.
Rijksweg 14
B-2870 Puurs, Belgium
Siegfried El Masnou, S.A.
Camil Fabra 58, El Masnou
08320 Barcelona, Spain
Novartis Pharma GmbH
Roonstrasse 25
D-90429 Nuremberg, Germany
InPharm Sp. z o.o.
ul. Strumykowa 28/11, 03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249, 04-458 Warsaw
Marketing authorization number in Croatia, the country of export:HR-H-257802614-01
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.